Onkologie. 2026:20(2):112-116 | DOI: 10.36290/xon.2026.021

Diabetes mellitus and neoplastic diseases

Andrea Křivanová
Interní hematologická a onkologická klinika, LF MU a FN Brno

Diabetes mellitus and cancer are considered to be the 4th, the 2nd respectively, cause of death in developed countries worldwide. The incidence and prevalence has increased in the last decade and continues to grow further, it is estimated that about 8-18 % of patients suffer from both - diabetes and cancer. Epidemiologic evidence suggests that people with diabetes 2nd type are at significantly higher risc for many forms of cancer. In the text we comment on an association between diabetes and the risk of cancer, possible biological background of this relationship and the influence of antidiabetic therapy to cancer and also anticancer therapy to the impairment of glucoregulation. The special attention is focused on pancreatic cancer and diabetes mellitus the 3rd type. The new field "diabeto-oncology" could be great suggestion for improving care of diabetic patients with cancer and guarantee the holistic medical care.

Keywords: diabetes, cancer, pancreatic cancer, diabeto-oncology, anticancer therapy and diabetes.

Accepted: April 20, 2026; Published: April 28, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Křivanová A. Diabetes mellitus and neoplastic diseases. Onkologie. 2026;20(2):112-116. doi: 10.36290/xon.2026.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 28.4.2027

    References

    1. Argenteri A, De Sabata MS, Ascoli Marchetti A. Readings on Diabetes. IDF Europe; 2024. doi: 10.13140/RG.2.2.34391.38564. Go to original source...
    2. Gallo M, Clemente G, Cristiano Corsi D, et al. An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience. Diabetes Res Clin Pract. 2020;159. Go to original source...
    3. Češka R, et al. Interna. 3. vydání. Praha: Triton, 2020; 970 s.
    4. Wilson EB, Maher HC. Cancer and tuberculosis with some comments on cancer and other diseases. Am J Cancer. 1932;16:227-250.
    5. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009; 52(9):1732-1744. Go to original source... Go to PubMed...
    6. American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes 2019. Diabetes Care. 2019;42(1):34-45. Go to original source... Go to PubMed...
    7. Carstensen B, Read SH, Friis, S et al. Diabetes and Cancer Research Consortium. Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia. 2016;59(5):980-988. Go to original source...
    8. Swerdlow AJ, Jones ME, Slater SD, et al. Cancer incidence and mortality in 23 000 patients with type 1 diabetes in the UK: long-term follow-up. Int J Cancer. 2023;153(3):512-523. Go to original source...
    9. Suh S, Kim KW. Diabetes and cancer: is diabetes causally related to cancer? Diabetes Metab J. 2011;35(3):193-198. Go to original source... Go to PubMed...
    10. Lohi P, Auvinen A, Niskanen L, et al. Does the duration of diabetes increase the risk of cancer? A nationwide population-based cohort of patients with new-onset diabetes and a matched reference cohort. Int J Cancer. 2024;154(11):1940-1947. Go to original source... Go to PubMed...
    11. Zavoral M, Vojtěchová G, Májek O, et al. Populační screening kolorektálního karcinomu v České republice. Cas Lek Cesk. 2016;155(1):7-12.
    12. Ling S, Zaccardi F, Issa E, et al. Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England. Diabetologia. 2023;66(4):657-673. Go to original source... Go to PubMed...
    13. Chen WY, Willett WC, Hankinson SE, et al. Long-term use of hormone therapy and breast cancer incidence and mortality. Cancer Res. 2012;72:(8_Supplement): LB-60. Go to original source...
    14. Natalicchio A, Montagnani M, Gallo M, et al. MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary critical view. ESMO Open. 2023;8(3):101573. DOI: 10.1136/esmoopen-2023-101573. Go to original source...
    15. Absolonová P, Trna J. Klinická studie ScrePAN. Florence. Praha: Care Comm, s. r. o.; 2024;3(1):12-13.
    16. Hart PA, Bellin MD, Andersen DK, et al. Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer(CPDPC). Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1(3):226-237. Go to original source...
    17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S5-20. Go to original source... Go to PubMed...
    18. Ewald N, Kaufmann C, Raspe A, et al. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012;28(4):338-342. Go to original source... Go to PubMed...
    19. Saruc M, Pour PM. Diabetes and its relationship to pancreatic carcinoma. Pancreas. 2003;26(4):381-387. Go to original source...
    20. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95-101. Go to original source...
    21. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2013;42(2):198-201. Go to original source... Go to PubMed...
    22. Arslan M, Ikram Z, Zahid R, et al. Type 3c Diabetes. A New Challenge of 2021 to Diabetologists. International J of Clinical Studies and Medical Case Reports. 13.10.??? Go to original source...
    23. Johnson CD, Arbuckle R, Bonner N, et al. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome (PRO) Instrument. Patient. 2017;10(5):615-628. Go to original source...
    24. Ewald N, Bretzel RG, et al. Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease? Eur J Intern Med. 2013;24:203-206. Go to original source...
    25. Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to determine risk of pancreatic cancer in patients with newonset diabetes. Gastroenterology [Internet]. 2018;155(3):730739. Go to original source...
    26. Mellenthin C, Meier CR, Jick SS, et al. Performance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data - a database study in the British population, Pancreatology. https://doi.org/10.1016/j.pan.2025.09. Go to original source...
    27. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S46-S59. Go to original source...
    28. Wolrab D, Jirásko R, Cífková E, et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun. 2022;13(1):124. Go to original source... Go to PubMed...
    29. Silvestris N, Franchina T, Gallo M, et al. Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper. ESMO Open. 2023;8(6). Go to original source...
    30. The Joint British Diabetes Societies (JBDS) for Inpatient Care group. Glycaemic management during the inpatient enteral feeding of stroke patients with diabetes. 2023. Available from: https:// abcd.care/resource/glycaemic-management-during-enteral-feeding-stroke.
    31. Kasuga M, Ueki K, Tajima N, et al. Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer. Cancer Sci. 2013;104(7):965-976. Go to original source...
    32. Jirkovská A Diabetes a nádorová onemocnění. Remedia. 2011;21.
    33. Petera J, Šmahelová A. Diabetes mellitus a zhoubné nádory. Vnitř Lék. 2014;60(10, Suppl 2):69-74.
    34. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732-175. Go to original source... Go to PubMed...
    35. Colhoun HM. SDRN Epidemiology Group. Use of insuline glargine and cancer incidence in Scotland: a study form the Scottish Diabetes Research Notwork Epidemiology Group. Diabetologia 2009;52(9):1755-1765. Go to original source...
    36. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766-1777. Go to original source...
    37. Taubes G. Cancer Research. Cancer prevention with a diabetes pill? Science. 2012;335(6064):29. Go to original source...
    38. Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE. 2012;7(3):e33411. DOI: 10.1371/journal.pone.0033411. Go to original source...
    39. Tesařová P. Metformin - nová hvězda onkologické léčby? Onkologie. 2012;6(2):82-84.
    40. Ahsan M, Khan A, Abbas S, et al. The Role of Metformin in cancer Prevention and Treatment: A Game Changer? J Oncol Res Ther. 2025;10:10296. Go to original source...
    41. Křivinka J, Dítě P, Mohelníková Duchoňová B. Karcinom pankreatu a diabetes mellitus. Vnitř Lék. 2025;71(8): 490-496. Go to original source...
    42. Perez A, Jansen-Chaparro S, Saigi I, et al. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6(1):9-20. Go to original source...
    43. Racil Z, Razga F, Drapalova J, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. 2013;98(10):e124-126. Go to original source... Go to PubMed...
    44. Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res. 2014;38(12): 1392-1398. Go to original source... Go to PubMed...
    45. Salaami O, Kuo CL, Drake MT, et al. Antidiabetic Effects of the Senolytic Agent Dasatinib. Mayo Clin Proc. 2021;96(12): 3021-3029. Go to original source... Go to PubMed...
    46. Lutz SZ, Ullrich A, Häring HU, et al. Sunitinib specifically augments glucose-induced insulin secretion. Cell Signal. 2017;36:91-97. Go to original source...
    47. Perdigoto AL, Quandt Z, Anderson M, et al. Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. Lancet Diabetes Endocrinol. 2019;7(6):421-423. Go to original source...
    48. Mizab M, Sánchez PM, Santos RMD, et al. Fulminant type 1 diabetes mellitus associated with pembrolizumab. Endocrinol Diabetes Nutr. 2017;64(5):272-273. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.